Ascend Gene & Cell Therapies
Freddie Dear is a seasoned professional in corporate development and investment management with a robust background in the biotech and therapeutic sectors. Currently serving as VP of Corporate Development at Ascend and Principal at Monograph Capital, Freddie Dear also holds the role of Investor Director at Nocion Therapeutics, Inc. Previous experience includes positions as a Board Observer at Clade Therapeutics, Forcefield Therapeutics, and Quell Therapeutics, as well as serving as an Investment Partner at Syncona Limited. A graduate of The University of Edinburgh, Freddie Dear earned a Bachelor of Science in Biochemistry and has also gained experience through various internships and roles, including time at Wellcome Trust and Tetragon Financial Group Limited.
This person is not in any offices
Ascend Gene & Cell Therapies
Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.